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Background: Lack of adherence to international normalised ratio (INR) monitoring in rheumatic heart disease (RHD)
patients is a contributor to cardio-embolic complications. This population-based observational study investigated
whether the distance between home and an INR clinic affects the maintenance of therapeutic INR in RHD patients
on warfarin.
Methods: Residential addresses, INR clinics, and INR results of patients with RHD were extracted from the Cape
Town component of the Global Rheumatic Heart Disease Registry (REMEDY) database. Addresses of homes and INR
clinics were converted to geographical coordinates and verified in ArcGIS 10®. ArcGIS 10® and Google Maps® were
used for spatial mapping and obtaining shortest road distances respectively. The travel distance between the home
and INR clinic was correlated with time within therapeutic range (TTR) using the Rosendaal linear interpolation
method, and with the fraction of INR within range, based on an average of three INR readings of patients and
compared with recommended therapeutic ranges.
Results: RHD patients (n = 133) resided between 0.2 km and 50.8 km (median distance, 3.60 km) from one of 33
INR clinics. There was no significant difference in the achievement of the therapeutic INR between patients who
travelled a shorter distance compared to those who travelled a longer distance (in range = 3.50 km versus out of
range = 3.75 km, p = 0.78). This finding was the same for patients with mechanical valve replacement (n = 105)
(3.50 km versus 3.90 km, p = 0.81), and native valves (3.45 km versus 2.75 km, p = 0.84).
Conclusions: There is no association between the maintenance of INR within therapeutic range amongst RHD
patients in Cape Town and distance from patients’ residence to the INR clinic.
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Various factors for non-adherence to health-related in-
terventions and monitoring have been suggested by the
World Health Organisation (WHO), including distance
decay [1, 2] Distance decay is a term given to describe
the effect of distance on interactions observed between
two locations; in this case, it is observed that travel dis-
tance to health services is inversely proportional to the* Correspondence: mark.engel@uct.ac.za
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health care disparities [3]. A recent study on distance
decay and clinic utilization in South Africa identified the
need to improve the quality of care in clinics in poorer
areas, thus potentially minimizing the distance travelled
to access health care in better resourced areas [4]; an
earlier study by Tanser et al. found evidence of distance
decay in primary health care utilization in South Africa
[5]. Elsewhere, a study on delivery care utilization in
Vietnam found an increased risk of neonatal mortality
among mothers living farthest away from a health facility
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with severity of illness; furthermore, the rate of clinic
visits decreased linearly at 0.5 km intervals and stabilised
after 4 km [7].
Rheumatic heart disease (RHD) is a condition charac-
terised by permanent heart valve damage, which may, in
severe cases, require corrective heart valve surgery [8, 9];
however, there is an additional risk of blood clot forma-
tion and/or embolism, which may result in stroke [10].
A higher risk of stroke is also associated with another
complication, namely atrial fibrillation [11]. Anticoagu-
lant drugs such as warfarin are thus prescribed. Anti-
coagulation therapy, which interferes with the clotting
process is highly effective at reducing the risk of stroke
[12, 13] but requires regular laboratory-guided adjust-
ments of the dose, as response to treatment is affected
by interactions with food and drugs [14, 15]. Monitoring
is done through the international normalized ratio
(INR), which represents the comparison of clotting times
in patients who have been prescribed anticoagulants
against the clotting times in healthy individuals. The
safety and effectiveness of anticoagulant therapy is cru-
cially dependent on maintaining the INR within the
therapeutic range [16, 17].
To the best of our knowledge, no studies exist on the
effect of distance decay on the maintenance of INR
therapeutic ranges among RHD patients. The primary
aim of this study, therefore, was to evaluate the effect of
distance on the maintenance of INR in the therapeutic
range amongst RHD patients on anticoagulant therapy.
Specifically, this study aimed to investigate whether the
distance of a patient’s residence from their INR clinic
impacts on maintaining INR levels within the recom-
mended therapeutic ranges over the scheduled monthly
visits to the clinic.
Methods
Study design
This was a population-based observational sub-study
nested within the Groote Schuur Hospital (GSH) cohort of
the Global Rheumatic Heart Disease Registry (REMEDY)
study, a multicenter, prospective hospital-based RHD re-
gistry [18]. The REMEDY project aims to provide compre-
hensive, contemporary data on patients with RHD so as to
aid the development of strategies to prevent and manage
RHD and its complications. This study is a retrospective
analysis of two methods for determining INR control and
evaluating the time within therapeutic range (TTR). The
TTR was calculated using the fraction of INRs in range,
based on the average of 3 INR readings [19] and the
Rosendaal linear interpolation method [20]. This study
was approved by the University of Cape Town Human
Research Ethics Committee, and all participants gave writ-
ten informed consent or assent.Recruitment and enrolment
All GSH patients diagnosed with RHD and treated with
warfarin in the REMEDY study, were eligible to partici-
pate in the study. Patients were excluded if their address
data were incomplete at their 12-month follow-up visit, if
they had not had a follow-up visit with INR data being re-
corded, or if they resided outside of the Cape Metropole
area, which is located in the Western Cape province of
South Africa.
Data
Patient data including demographic details, residential ad-
dresses and clinical data, such as diagnosis of RHD, INR
readings and referral INR clinics were extracted from
REMEDY patient records and captured into a purpose-
designed database. Evidence-based clinical guidelines
guide INR therapeutic level ranges for patients, which are
between 2.00 and 3.00 for patients without valve replace-
ments and between 2.5 and 3.5 for patients with mecha-
nical prosthetic valve replacements [16]. Patient addresses
were converted to geographical coordinates obtained from
Google Earth®, while government clinics were mapped
using information supplied by the Department of Surveying
and Mapping in Mowbray, Cape Town.
Geographical information systems
This study utilized Geographical Information System
(GIS) software, ArcGIS 10®, for capturing, manipulating,
managing, analysing and displaying spatial and non-spatial
data. In brief, GIS overlaps layers of information within a
geographical area to give a better understanding from a
composite viewpoint [21]. Information about geographical
features (roads, boundaries etc.) was accessed from the
ESRI database (https://www.arcgis.com). Data were pro-
jected in the Universal Transverse Mercator (UTM) sys-
tem. The shortest road travel distances between homes
and the health facility utilized by patients for INR moni-
toring were calculated using Google Maps (https://maps.
google.co.za/maps?hl=en) and entered into the study data-
base. Linear distances between the patient’s home and
closest health facility were calculated using the “near”
function in the “proximity” toolbox in ArcMap 10®. The
geocoded addresses were checked in ArcGIS for errors in
coordinate data. Distances mentioned are all one-way
distances.
Statistical analysis
Statistical analyses and data handling were performed
using STATA® version 11 and ArcGIS® version 10. We
evaluated INR readings as a whole, as well as stratified
according to valve type. Pearson’s chi-squared test and
Mann–Whitney U test were used for group comparisons
with a p-value of < 0.05 considered as being significant.
The road travel distances between individual residential
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age of the latest three INR measurement readings of the
patient. Standard deviation (SD) and 95 % confidence in-
tervals (CI) were used to evaluate data dispersion.
Results
One-hundred and thirty-three patients enrolled at GSH
in the REMEDY database met the inclusion criteria.
Eighty-three percent of the cohort was female (n = 110)
and 79 % of patients (n = 105) had had mechanical valve
replacements (MVRs). Co-morbidities included hyperten-
sion (27 %), stroke (25 %) and diabetes (19 %) (Table 1).
Among the participants excluded due to unavailability of
address details or INR data, 185 (83 %) were female and
81 (36 %) had had MVRs; the median age was 46 years
(16–79 years).
Figures 1 and 2 represent the spatial orientation of the
RHD patients’ residences and the INR clinics in the Cape
Metropole region. INR monitoring was conducted among
33 clinics across the Cape Metropole. Road distances were
not normally distributed; the median distance between the
patient’s residences and their respective clinics was
3.60 km (range, 0.2 km–50.8 km). Figure 2 displays the
clinics utilized by RHD patients for INR monitoring as
well as clinics not currently used for INR monitoring. The
geographical distribution of these clinics indicates that
patients could instead be utilizing clinics closer to their
residences.
Three-hundred and thirty-four INR values were in-
cluded in the analysis. The mean TTR over the study
period for the fraction of INR’s in range for MVR and
non-MVR patients was 0.42 (95 % confidence interval
(CI), 0.31; 0.53) and 0.67 (95 % CI, 0.53; 0.78) respec-
tively. Table 2 provide the details pertaining to seven
clinics utilized by 3 or more patients for INR monitoring,Table 1 Baseline characteristics of participants
Number Percent
Patients who completed >12 month follow-up and
for whom address and INR data were available
133
Average age (SD) 53 years (1.25)
Female 110 83
No of patients with mechanical valve replacement 105 79







N total number of patients, % percentage, SD standard deviation, n number of
patients who suffer from co-mobidities
aData were not available on all patientsindicating the number of patients who maintained thera-
peutic levels according to whether or not they had had a
MVRs. Overall, patients with mechanical valves were less
likely to be within their therapeutic INR range than pa-
tients with native valves (OR: 0.32, 95 % CI: 0.11, 0.86).
Using the Rosendaal method, TTR values for MVR and
non-MVR patients were 0.38 and 0.58 respectively.
Among all the patients in our cohort, those who main-
tained their INR within recommended therapeutic levels
travelled a shorter median distance to their designated
INR clinic (3.50 km versus 3.75 km) (Table 3). However,
this association was not statistically significant (p = 0.78).
This trend was also observed within the MVR subset
of patients (n = 105) (in range = 3.50 km versus out of
range = 3.90 km, p = 0.81). This trend however, con-
trasted with patients with native valves (n = 28), where
the patients who maintained therapeutic levels travelled
a further median distance to their designated clinics
(3.45 km versus 2.75 km, p = 0.84).
Figure 3 depicts the distance of the closest clinic rela-
tive to the patient’s home address; the median distance
from the patients’ residence to the closest clinic is
0.67 km (0.08–2.80).
Discussion
Our study demonstrates that was no difference in the me-
dian distance from an RHD patient’s residence to their
designated INR clinic in respect of those who maintained
their INR readings within the therapeutic range versus
those who did not (3.50 km versus 3.75 km; p = 0.78). Pa-
tients attending Groote Schuur Hospital (GSH), the only
tertiary hospital included among the INR clinics, travelled
a median distance of 18.2 km (1.6 km–50.8 km), which
was noticeably further than the median road distance of
3.60 km travelled by patients overall to treatment facilities.
Reasons for this may include a possible perception of
higher quality care or convenience associated with GSH, if
located near to a place of employment [22]. The overall
proportion of patients within the target INR therapeutic
range was 50.3 %. Given that target INR differs according
to whether patients had undergone a mechanical valve re-
placement (MVR) or not (i.e., 2.0–3.0 for no or biological
valve replacement, and 2.5–3.5 for MVR), we also consi-
dered MVR patients separately. No statistically significant
association was established between distance and main-
tenance of INR therapeutic levels among MVR patients.
The TTR values obtained using the Rosendaal interpolated
method confirmed the trends calculated by the fraction
method. However, it must be borne in mind that the
Rosendaal method tends to deflate the TTR, for reasons
which are unclear [19].
Participants for our study needed to have at least two
INR readings, to reside within the geographical metro-
politan area served by the hospital, and to have complete
Fig. 1 Map of the Cape Metropole showing patients’ residences and the clinics utilized for INR monitoring. Each blue circle represents a patient’s
residence; each red cross represents the INR clinics utilized by RHD patients
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Participants excluded from the study were similar as
regards gender and mean age; of these, 79 % had MVRs.
Unfortunately, we did not have correlates for missing
data, such as socio-economic status, and thus could not
perform correlation analysis to impute the likelihood of
distance barriers.
We made use of both linear and road distances in our
analysis. The shortest road travel distances between pa-
tients’ homes and health facilities were measured using
Google Maps®. The median distance to the closest health
facility from patients’ residences, using linear distance
measurement was 0.67 km. The extent to which the
straight-line distance measurement is used as a proxy
for true distance is sometimes questionable and raises
concern, when a particular geographical area of study
has diverse features, for example, in vast mountainous
areas, where there is limited road access. In this study,
the geographical area has a good road infrastructure and
is not affected by diverse geographical features, thus we
are confident that the straight-line distance measure-
ment used in this setting is closely representative of the
true road distance travelled. Furthermore, straight-linedistances have previously been used in many studies in-
cluding those from Vietnam and Kenya discussed below.
Published studies that evaluated the effect of patients’
travel distance on utilization of health services report re-
sults, which differ from ours. A neonatal mortality study
conducted in Vietnam showed an increased risk of neo-
natal mortality among mothers living farthest away from
a health facility [6]. In another study, conducted in
Kenya, it was found that younger children and children
with more severe illnesses travelled a further median dis-
tance to a health facility compared with older children
with less serious illnesses; the rate of clinic visits de-
creased linearly at 0.5 km intervals and stabilised beyond
4 km [7]. These findings, unlike ours, are in keeping
with the suggestion that out of pocket expenses may be
a barrier to adherence, given that longer travel distances
imply greater expense [23].
Some study limitations should be acknowledged.
Firstly, the sample size was small. Thus, even though a
trend of distance decay was seen among patients who
have had MVRs, the association failed to reach statistical
significance. Secondly, the relatively short median dis-
tances travelled by participants in Cape Town may limit
Fig. 2 Map of the Cape Metropole showing patients’ residences (blue circles), the clinics utilized for INR monitoring (red cross within white circle)
and clinics that could potentially be used for INR monitoring within closer proximity to patients’ residences (red cross within a yellow circle)
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sible that distance decay may be a factor in median dis-
tances of more than 50 km. Lastly, this study only
focused on one of the many factors that influence adhe-
rence (travel distance only, but not considering out ofTable 2 Shortest median road distance from patients’ homes to
health facilities
Obs No. in INR range Median km (range)
MVR = no MVR = yes
All clinics 133 20/28 (71) 47/105 (45) 3.60 (0.2–50.8)
Individual clinicsa
GSH 35 5/7 (71) 15/28 (54) 18.2 (1.6–50.8)
Dr Abdurahman CHC 10 0 3/10 (30) 2.95 (1.0–5.4)
Mitchell’s Plain CHC 21 1/4 (25) 7/17 (41) 2.8 (1.2–5.6)
Heideveld CHC 10 1/2 (50) 3/8 (38) 2.75 (1.6–6.5)
Hanover Park CHC 8 1/1 (100) 4/7 (57) 1.1 (0.2–9.1)
Lady Michaelis CHC 5 1/2 (50) 1/3 (33) 6.4 (1.8–14.0)
Woodstock CHC 4 1/2 (50) 1/2 (50) 1.55 (0.4–14.9)
Obs observations, No number, km kilometres, MVR mechanical valve
replacement, GSH Groote Schuur Hospital, CHC community health clinic
aOnly clinics with 3 or more patients were evaluatedpocket expenses, the use of public transport and patient
waiting times at respective facilities to mention but a
few. Given the scope of the data in the registry, informa-
tion related to the mode of transport used to health fa-
cilities was not recorded. However, anecdotally mostTable 3 Median shortest road travel distance from patients’
homes to health facilities, overall and by valve type
n (%) Median km
All patients
Out of therapeutic range 66 (49.6) 3.75 (0.4–50.8) p = 0.78
In therapeutic range 67 (50.4) 3.50 (0.2–30.8)
Total 133 (100)
Mechanical valve = yes
Out of therapeutic range 58 (55) 3.90 (0.4–50.8) p = 0.81
In therapeutic range 47 (45) 3.50 (0.2–30.8)
Total 105 (100)
Mechanical valve = no
Out of therapeutic range 8 (29) 2.75 (1.2–18.2) p = 0.84
In therapeutic range 20 (71) 3.45 (1.0–24.0)
Total 28 (100)
n number of observations, % percentage, km kilometres
Fig. 3 Map showing the patients’ residences (blue circles) and INR clinics (red cross within circle) using graduated symbology to represent the
distance to the nearest clinic for potential INR monitoring, represented by graduated circles in size and colour ranging from yellow (0–0.5 km) to
red (1.5–2.8 km)
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transport, which incorporates an extensive network of
taxi services with travel times per km being largely uni-
form. Further factors influencing patient INR main-
tenance could be gleaned by future studies incorporating
qualitative methods to evaluate issues such as socio-
economic status.
In summary, GIS has proven to be a useful tool for
evaluating the utilization of clinics for INR monitoring.
This study indicates that there is perhaps a need to
establish INR facilities within existing clinics closer to
patients’ residences; if patients utilize a clinic in their
neighborhood or nearest to their place of residence, it
could reduce travelling time and out of pocket expenses
associated with transport costs and facilitate their access
to healthcare. Furthermore, the load on already over-
burdened clinics would be more appropriately spread.
Conclusions
The results of this study do not provide evidence for an
association between the distance from RHD patients’
residences to their INR clinics and the maintenance ofINR therapeutic ranges, irrespective of whether patients
had had MVRs or not. This finding was consistent
among patients attending the tertiary hospital and
community-based clinics. Patients in our cohort were
not found to utilize the clinic closest to their residence,
but instead travelling on average up to three times fur-
ther for their INR monitoring.
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